Home / Business and Economy / Hantavirus Outbreak Boosts Moderna Shares
Hantavirus Outbreak Boosts Moderna Shares
11 May
Summary
- Moderna's mRNA platform is being eyed for hantavirus vaccine potential.
- An outbreak of Andes strain hantavirus has raised concerns globally.
- Moderna stock shows significant gains, outpacing market indices.
Moderna's stock experienced a significant rally following reports of a hantavirus outbreak. Three fatalities were linked to the Andes strain on the MV Hondius cruise ship, with a U.S. national also testing positive. This particular strain's potential for human-to-human transmission and the absence of an approved vaccine have focused investor attention on Moderna's research.
Moderna is advancing hantavirus research using its mRNA platform, collaborating with the U.S. Army Medical Research Institute of Infectious Diseases and Korea University. This positions the company's technology as a potential rapid response tool for emerging infectious threats. The stock's performance reflects this specific development, showing an 8.46% increase in pre-market trading on May 11, 2026.
Analyst sentiment remains mixed, with a consensus 'Hold' rating and an average price target of $41.67. However, recent analyst actions in early May 2026 saw target increases from UBS, Goldman Sachs, and Evercore ISI Group. Technically, the stock is trading above key moving averages, though a short-term bearish crossover on the 20-day and 50-day SMAs suggests consolidation. Momentum indicators like MACD suggest improving upside pressure.
